Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 14/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17475441 | 0.91 | BDKRB2 (0.57) | BDKRB2 | |
| SCHEMBL17475443 | 0.90 | BDKRB2 (0.61) | BDKRB2 | |
| SCHEMBL17475458 | 0.84 | BDKRB2 (0.45) | BDKRB2 | |
| SCHEMBL17475445 | 0.83 | BDKRB2 (0.51) | BDKRB2 | |
| SCHEMBL6578892 | 0.82 | BDKRB2 (0.57) | BDKRB2 | |
| SCHEMBL8361694 | 0.82 | BDKRB2 (0.79) | BDKRB2 | |
| SCHEMBL7749671 | 0.82 | BDKRB2 (0.70) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL7750241 | 0.81 | BDKRB2 (0.70) | BDKRB2 | |
| SCHEMBL6578818 | 0.81 | BDKRB2 (0.56) | BDKRB2 | |
| SCHEMBL17475444 | 0.80 | BDKRB2 (0.70) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | claimed |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | BDKRB2, BDKRB1, HRH2 | BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.